Dasatinib,nilotinib,ponatinibandbosutinibare second-generation multi-targeted TK inhibitors that are used for treatment of Ph+CML with acquired BCR-ABL mutations [41]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.